-+ 0.00%
-+ 0.00%
-+ 0.00%

Guggenheim Downgrades enGene Therapeutics to Neutral

Benzinga·05/08/2026 12:51:07
Listen to the news
Guggenheim analyst Michael Schmidt downgrades enGene Therapeutics (NASDAQ:ENGN) from Buy to Neutral.